Last $2.19 USD
Change Today -0.04 / -1.79%
Volume 112.6K
OXGN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

oxigene inc (OXGN) Snapshot

Open
$2.19
Previous Close
$2.23
Day High
$2.21
Day Low
$2.16
52 Week High
03/12/14 - $5.40
52 Week Low
02/12/14 - $1.96
Market Cap
45.3M
Average Volume 10 Days
255.5K
EPS TTM
$-2.90
Shares Outstanding
20.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXIGENE INC (OXGN)

oxigene inc (OXGN) Related Bloomberg News

View More Bloomberg News

oxigene inc (OXGN) Related Businessweek News

No Related Businessweek News Found

oxigene inc (OXGN) Details

OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops therapeutics primarily to treat cancer. The company focuses on developing vascular disrupting agents (VDAs) that disrupt abnormal blood vessels associated with solid tumor progression. Its principal clinical product candidate is ZYBRESTAT, which is in development as a treatment for solid tumors. The company is also developing OXi4503, a second-generation product candidate for acute myeloid leukemia. OXiGENE, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

9 Employees
Last Reported Date: 03/20/14
Founded in 1988

oxigene inc (OXGN) Top Compensated Officers

Chief Financial Officer and Principal Account...
Total Annual Compensation: $241.3K
Compensation as of Fiscal Year 2013.

oxigene inc (OXGN) Key Developments

OXiGENE, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

OXiGENE, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $3.924 million compared to a net loss of $1.655 million for the comparable three-month period in 2013. The increase in the net loss in 2014 as compared to 2013 was primarily due to an increase in research and development (R&D) expenses of approximately $1.6 million in the second quarter of 2014 as compared to the prior year period. Loss from operations was $3,924,000 compared to $1,655,000 a year ago. Net loss attributable to common stock was $3,929,000 compared to $4,135,000 a year ago. Basic and diluted net loss per share attributable to common stock was $0.23 compared to $1.86 a year ago. For the six months, the company reported net loss of $6,559,000 compared to $3,534,000 a year ago. Loss from operations was $6,552,000 compared to $3,536,000 a year ago. Net loss attributable to common stock was $6,559,000 compared to $6,015,000 a year ago. Basic and diluted net loss per share attributable to common stock was $0.50 compared to $2.89 a year ago.

OXiGENE, Inc. to Report Q2, 2014 Results on Aug 05, 2014

OXiGENE, Inc. announced that they will report Q2, 2014 results at 8:00 PM, GMT Standard Time on Aug 05, 2014

OXiGENE, Inc., Q2 2014 Earnings Call, Aug 05, 2014

OXiGENE, Inc., Q2 2014 Earnings Call, Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXGN:US $2.19 USD -0.04

OXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXGN.
View Industry Companies
 

Industry Analysis

OXGN

Industry Average

Valuation OXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 405.1x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 104.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXIGENE INC, please visit www.oxigene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.